Transdermal Patches and Topical Serums

Cream, gel, serum, and patch formats with permeation enhancers for topical and transdermal delivery of bioregulators.

Topical and transdermal delivery applies a bioregulator compound to the surface of the skin in a vehicle engineered for either local cutaneous action (topical) or systemic absorption through the skin into the circulation (transdermal). The two routes share the same anatomical interface — the stratum corneum, the dermis, and the cutaneous microvasculature — but differ in their formulation goals: a topical seeks to retain the compound in the epidermis and superficial dermis; a transdermal seeks to deliver the compound past those layers and into the bloodstream.

The defining technical problem of skin delivery is the stratum corneum — the outermost fifteen to twenty micrometers of the epidermis, composed of dead, keratinized corneocytes embedded in an intercellular lipid matrix of ceramides, cholesterol, and free fatty acids. This structure is a near-perfect barrier to most water-soluble compounds and to most molecules above five hundred daltons in molecular weight. The science of dermal and transdermal delivery is the science of crossing this barrier in a controlled, reproducible way.

For peptide bioregulators, formulation strategy combines vehicle chemistry (cream, gel, serum, patch), permeation enhancer selection (chemical, physical, or carrier-based), and where appropriate, integration with microneedle, iontophoretic, or sonophoretic delivery technologies described in the related platforms within this cluster.

A documented format in pharmaceutical practice.

Topical preparations are among the earliest documented forms of pharmaceutical practice. Ointments, salves, and cold creams appear throughout ancient medical literature and were formalized as a class in the nineteenth-century pharmacopoeias. The deliberate engineering of skin formulations for systemic drug delivery, however, is a modern development. The first commercial transdermal patch — scopolamine for the prevention of motion sickness — received regulatory approval in 1979 and established the principle that controlled, multi-day systemic drug delivery through intact skin was a viable pharmaceutical route.

The 1980s and 1990s saw rapid expansion of the transdermal category. Nitroglycerin patches for angina (1981), clonidine for hypertension, estradiol for hormone replacement, testosterone, fentanyl for chronic pain, and nicotine patches for smoking cessation all reached the market. The 2000s extended the category into central-nervous-system indications with methylphenidate for attention-deficit disorders, rivastigmine for Alzheimer's disease, and rotigotine for Parkinson's disease. Selegiline reached the transdermal market for major depressive disorder. Each of these products demonstrated that compounds previously thought confined to oral or injectable delivery could be re-engineered for the transdermal route.

In parallel, the topical and cosmetic-pharmaceutical literature established peptide compounds as legitimate active ingredients for skin-directed formulations. The copper-bound tripeptide glycyl-L-histidyl-L-lysine (GHK-Cu) was identified in the early 1970s and has been studied continuously since as a modulator of wound healing, collagen synthesis, and tissue regeneration. Palmitoyl pentapeptide-4 (Matrixyl) and acetyl hexapeptide-8 (Argireline) followed, establishing the cosmetic-peptide category. The application of short peptide bioregulators in topical and transdermal vehicles is therefore not a novel pharmaceutical direction but a continuation of a fifty-year arc.

The format today encompasses creams, gels, serums, ointments, sprays, and a range of patch architectures — reservoir, matrix, drug-in-adhesive, and microreservoir — each engineered for specific compound profiles and dosing regimens. The current regulatory framework distinguishes cosmetic formulations governed under MoCRA from over-the-counter and prescription drug products governed under the appropriate FDA pathway.

How the format delivers.

A molecule applied to intact skin can follow three primary penetration pathways. The intercellular route — diffusion through the lipid matrix surrounding the corneocytes of the stratum corneum — is the dominant pathway for most lipophilic compounds. The transcellular route — passage through the corneocytes themselves — contributes for compounds with mixed hydrophilic and lipophilic character. The transappendageal route — passage through hair follicles, sebaceous glands, and sweat ducts — accounts for less than one percent of total skin surface area but disproportionately serves the delivery of polar molecules, larger compounds, and particulate carriers.

The classical predictors of skin permeation are molecular weight, lipophilicity, and ionization state. The widely cited five-hundred-dalton rule holds that compounds above this molecular weight rarely permeate intact skin in pharmacologically meaningful quantities without enhancement. Octanol-water partition coefficients (log P) between one and three predict optimal passive diffusion; values too low (highly hydrophilic) or too high (highly lipophilic) reduce permeation, in the former case through poor stratum-corneum partitioning and in the latter through sequestration in skin lipids without onward release to viable epidermis.

Most peptide bioregulators are larger and more polar than these predictors favor. Formulation therefore typically incorporates one or more permeation-enhancement strategies. Chemical enhancers — alcohols, glycols, terpenes, fatty acids, fatty esters, surfactants, azone — disrupt or fluidize the stratum-corneum lipid matrix. Vehicle engineering — propylene glycol systems, ethosomes, transferosomes, niosomes, and other lipid carriers — modifies partitioning and depot formation. Physical methods — iontophoresis, sonophoresis, microneedles — are detailed in their own platforms within this cluster and can be combined with the topical vehicle for enhanced delivery.

Pharmacokinetically, topical formulations produce predominantly local effect with limited systemic exposure. Transdermal systems are characterized by a lag time of thirty minutes to twelve hours before steady-state plasma levels develop, by sustained release over twelve hours to seven days depending on patch architecture, and by the avoidance of the high peak-trough variability characteristic of oral dosing. Skin itself serves as a depot, and circulating concentrations decline gradually after patch removal rather than terminating abruptly.

Bioregulators formulated for this platform.

Tetrapeptide-AEDG, Tripeptide-KED, Copper Tripeptide-1 (GHK-Cu), and selected analogs formulated for topical and transdermal absorption.

See the full bioregulator class and the per-compound published literature for compound-specific research references.

Classification and oversight.

Cosmetic (MoCRA) and OTC monograph pathways for consumer use; 503A compounding for clinical applications.

Detailed regulatory analysis — agency-specific requirements, classification thresholds, and pathway-specific labeling considerations — forthcoming.

The format in the scientific literature.

Topical and transdermal delivery is supported by an extensive peer-reviewed literature spanning fifty years of formulation science, skin pharmacokinetics, and clinical translation. The following references are foundational and review-level publications establishing the format as a documented pharmaceutical category, the molecular constraints on skin permeation, the chemical and physical enhancement strategies that overcome those constraints, and the cosmetic-peptide tradition into which short bioregulator peptides extend.

Compound-specific research on the bioregulators formulated for this platform appears in the per-compound subsections of the published literature archive.

The Atumnus Dermatrix™ platform.

The Dermatrix™ platform is the Atumnus patent-pending embodiment of Transdermal Patches and Topical Serums. It is licensed to operating affiliates for commercial development across the Opticeutical and Endoceutical tiers, and is one of the branded delivery technologies that anchors the Atumnus intellectual-property estate.

The Dermatrix™ trademark and associated patent-pending technology are held by Atumnus LLC, the founding entity of endogenic pharmacology. See affiliated entities for institutional structure.

Adjacent delivery formats.

Within the same cluster (Topical and Transdermal Delivery), see the full set of delivery platforms in this category.

← Back to all delivery platforms